Limitations and strengths of spontaneous reports data.

US Food and Drug Administration (FDA) monitoring of the continued safety of marketed medical products depends greatly on spontaneous reporting of serious adverse events by health professionals. Despite its inherent limitations, the national postmarketing surveillance system provides vital information of clinical importance.

[1]  L Lasagna,et al.  Adverse drug reactions—a matter of opinion , 1976, Clinical pharmacology and therapeutics.

[2]  D. Knapp,et al.  Discovery of new adverse drug reactions. A review of the Food and Drug Administration's spontaneous reporting system. , 1984, JAMA.

[3]  A. Hartzema,et al.  Drug Utilization Study Methodologies: National and International Perspectives , 1987, Drug intelligence & clinical pharmacy.

[4]  G. Faich,et al.  Rhode Island physicians' recognition and reporting of adverse drug reactions. , 1987, Rhode Island medical journal.

[5]  A. Fletcher,et al.  Spontaneous Adverse Drug Reaction Reporting Vs Event Monitoring: A Comparison , 1991, Journal of the Royal Society of Medicine.

[6]  R. Temple,et al.  Adverse effects of newly marketed drugs. , 1979, The New England journal of medicine.

[7]  Sachs Rm,et al.  An evaluation of spontaneous adverse drug reaction monitoring systems. , 1986 .

[8]  S. Cochi,et al.  The Vaccine Adverse Event Reporting System (VAERS). , 1994, Vaccine.

[9]  E. Loupi,et al.  Does Proof of Causality Ever Exist in Pharmacovigilance? , 1993, Drug safety.

[10]  D. J. Finney,et al.  The detection of adverse reactions to therapeutic drugs. , 1982, Statistics in medicine.

[11]  D. M. Green.  PRE-EXISTING CONDITIONS, PLACEBO REACTIONS, AND "SIDE EFFECTS". , 1964, Annals of internal medicine.

[12]  P. Tugwell,et al.  Pharmacoepidemiology: CurrentStatus, Prospects, and Problems , 1990 .

[13]  G. Weissmann,et al.  Advances in inflammation research , 1979 .

[14]  D. J. Finney,et al.  Statistical Aspects of Monitoring for Dangers in Drug Therapy) , 1971, Methods of Information in Medicine.

[15]  M D Rawlins,et al.  Pharmacovigilance: Paradise Lost, Regained or Postponed? , 1995, Journal of the Royal College of Physicians of London.

[16]  D. Lowenthal,et al.  Adverse nondrug reactions. , 1968, The New England journal of medicine.

[17]  B Begaud,et al.  False-positives in spontaneous reporting: should we worry about them? , 1994, British journal of clinical pharmacology.